Central nervous system progression in advanced non-small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study
- Resource Type
- Journal
- Source
BMC CANCER ; APR 4 2017, 17 p245 8p.- Subject
- Language
- English
- ISSN
- 14712407